PT - JOURNAL ARTICLE AU - Niamh Allen AU - Melissa Brady AU - Antonio Isidro Carrion Martin AU - Lisa Domegan AU - Cathal Walsh AU - Elaine Houlihan AU - Colm Kerr AU - Lorraine Doherty AU - Joanne King AU - Martina Doheny AU - Damian Griffin AU - Maria Molloy AU - Jean Dunne AU - Vivion Crowley AU - Philip Holmes AU - Evan Keogh AU - Sean Naughton AU - Martina Kelly AU - Fiona O’Rourke AU - Yvonne Lynagh AU - Brendan Crowley AU - Cillian de Gascun AU - Paul Holder AU - PRECISE Study Steering Group AU - Colm Bergin AU - Catherine Fleming AU - Una Ni Riain AU - Niall Conlon TI - SARS-CoV-2 Antibody Testing in Healthcare Workers: a comparison of the clinical performance of three commercially available antibody assays AID - 10.1101/2021.05.25.21257772 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.25.21257772 4099 - http://medrxiv.org/content/early/2021/05/26/2021.05.25.21257772.short 4100 - http://medrxiv.org/content/early/2021/05/26/2021.05.25.21257772.full AB - SARS-CoV-2 antibodies are an excellent indicator of past COVID-19 infection. As the COVID-19 pandemic progresses, retained sensitivity over time is an important quality in an antibody assay that is to be used for the purpose of population seroprevalence studies.We compared 5788 healthcare worker (HCW) serum samples on two serological assays (Abbott SARS-CoV-2 anti-nucleocapsid IgG and Roche Anti-SARS-CoV-2 anti-nucleocapsid Total Antibody) and a subset of samples (all Abbott assay positive or grayzone, n=485) on Wantai SARS-CoV-2 anti-spike Antibody ELISA. For 367 samples from HCW with previous PCR-confirmed SARS-CoV-2 infection we correlated the timing of infection with assay results.Overall seroprevalence was 4.2% on Abbott, 9.5% on Roche. Of those with previously confirmed infection, 41% (150/367) and 95% (348/367) tested positive on Abbott and Roche respectively. At 21 weeks (150 days) after confirmed infection, positivity on Abbott started to decline. Roche positivity was retained for the entire study period (33 weeks). Factors associated (P≤ 0.050) with Abbott seronegativity in those with previous PCR-confirmed infection included sex (male OR0.30;95%CI0.15-0.60), symptom severity (OR0.19 severe symptoms;95%CI0.05-0.61), ethnicity (OR0.28 Asian ethnicity;95%CI0.12-0.60) and time since PCR diagnosis (OR2.06 for infection 6 months previously;95%CI1.01-4.30. Wantai detected all previously confirmed infections.In our population, Roche detected antibodies up to at least seven months after natural infection with SARS-CoV-2. This may indicate that Roche is better suited than Abbott to population-based studies. Wantai demonstrated high sensitivity but sample selection was biased. The relationship between serological response and functional immunity to SARS-CoV-2 infection needs to be delineated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Irish Health Service Executive COVID-19 budget. NCs work is part-funded by a Science Foundation Ireland (SFI) grant. Grant Code 20/SPP/3685Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the National Research Ethics Committee for COVID-19 in Ireland (20-NREC-COV-101).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDataset has not been made available as may identify individual participants. Dataset can be made available upon reasonable request to the Principal Investigator.